2,5-Dimethoxy-4-ethoxyamphetamine
2,5-Dimethoxy-4-ethoxyamphetamine is a psychedelic drug of the phenethylamine, amphetamine, and DOx families. It was first described by Alexander Shulgin by 1968.
Use and effects
In his book PiHKAL, Alexander Shulgin lists MEM's dose as 20 to 50mg orally and its duration as 10 to 14hours. Its effects have been reported to include color enhancement, visual phenomena, and pattern movement, among others.
Pharmacology
Pharmacodynamics
MEM is a serotonergic psychedelic and acts as a selective serotonin 5-HT2 receptor agonist. It is specifically a full agonist of the serotonin 5-HT2A and 5-HT2C receptors and to a lesser extent is a partial to full agonist of the serotonin 5-HT2B receptor. The psychedelic effects of MEM are thought to be mediated by serotonin 5-HT2A receptor activation.
Chemistry
MEM, also known as 2,5-dimethoxy-4-ethoxyamphetamine, is a phenethylamine, amphetamine, and DOx derivative. It is the analogue and derivative of 2,4,5-trimethoxyamphetamine in which a 4-ethoxy group is present instead of a 4-methoxy group.
Synthesis
The chemical synthesis of MEM has been described.
Derivatives
A variety of derivatives of MEM have been developed and studied, for instance by Daniel Trachsel and colleagues. These include MPM, MIPM, MALM, MMALM, MFEM, MDFEM, and MTFEM, among others.
History
MEM was first synthesized by Alexander Shulgin. It was first described by him in the scientific literature by 1968. Subsequently, Shulgin described MEM in greater detail in his 1991 book PiHKAL.
Legal status
Canada
MEM is a controlled substance in Canada.
United States
MEM is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.